REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedRandomized Controlled TrialHuman Subjects

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Rubino Domenica, Abrahamsson Niclas, Davies Melanie, Hesse Dan, Greenway Frank L, Jensen Camilla, Lingvay Ildiko, Mosenzon Ofri, Rosenstock Julio, Rubio Miguel A
JAMA2021DOI: 10.1001/jama.2021.3224
semaglutideGLP-1 receptor agonist

Quality Score

7/10

Citations

0

Subjects

Human

PeptideVault Analysis

Study Design

As a randomized controlled trial, this study represents the highest tier of clinical evidence. The randomized design controls for confounding variables, making causal inferences more robust than observational studies.

Our Assessment

Quality Assessment: 7/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

The results for semaglutide, GLP-1 receptor agonist are encouraging. Critically, these findings come from human data — not animal models or in-vitro work — which makes them directly relevant to clinical applications. The study design adds significant weight to these conclusions.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. Specifically: the follow-up period was relatively short — long-term efficacy and safety remain open questions. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: This is high-quality human evidence for semaglutide, GLP-1 receptor agonist. If you're tracking the research landscape for these compounds, this paper deserves a close read.

Key Findings

The study found that continued weekly subcutaneous semaglutide treatment resulted in sustained weight loss compared to switching to placebo, with significant improvements in waist circumference and systolic blood pressure.

Limitations

The study had a relatively short follow-up period of 68 weeks, which may not be sufficient to assess long-term efficacy and safety. Additionally, the study excluded participants with diabetes, limiting generalizability to this population.

PeptideVault Analysis

Highlighting the efficacy and importance of continued GLP-1 receptor agonist therapy, specifically semaglutide, in maintaining weight loss for patients with obesity or overweight.

semaglutideGLP-1 receptor agonist

Maintaining Weight Loss with Semaglutide: A New Hope for Obesity Management

Published: May 17, 2026 | Source: JAMA (2021) | Category: semaglutide, GLP-1 receptor agonist

Overview

A recent study published in the Journal of the American Medical Association (JAMA) highlights the efficacy of continued weekly subcutaneous semaglutide treatment for maintaining weight loss in adults with overweight or obesity. This research underscores the importance of sustained therapy using glucagon-like peptide 1 (GLP-1) receptor agonists like semaglutide to achieve long-term health benefits.

Study Background

Before this study, it was unclear whether continuing GLP-1 receptor agonist treatment after initial weight loss would be necessary for maintaining those results. Previous research had shown that these medications are effective in inducing significant weight loss, but questions remained about the optimal duration of therapy and whether patients could maintain their weight without continued medication.

What the Research Found

The STEP 4 randomized clinical trial involved 803 participants who initially received semaglutide for a 20-week period. After reaching a maintenance dose, these individuals were randomly assigned to either continue with semaglutide or switch to placebo for an additional 48 weeks. The primary outcome was the percentage change in body weight from week 20 to week 68.

The results showed that participants who continued taking semaglutide maintained their weight loss, experiencing a further reduction of -7.9% on average compared to those who switched to placebo, whose weight increased by +6.9%. Additionally, the study observed significant improvements in waist circumference and systolic blood pressure among those continuing with semaglutide.

What This Means for Peptide Users

For individuals using GLP-1 receptor agonists like semaglutide for weight management, this research suggests that discontinuing treatment may lead to rapid weight regain. Therefore, patients should consider the long-term benefits of sustained therapy and discuss continuation plans with their healthcare providers to ensure continued health improvements.

Limitations and Caveats

While the study provides valuable insights into the role of semaglutide in maintaining weight loss, it has several limitations. The relatively short follow-up period of 68 weeks may not be sufficient to assess long-term efficacy and safety. Additionally, participants with diabetes were excluded from this trial, which limits its applicability to a broader population.

How This Compares to Previous Research

Previous studies have also highlighted the effectiveness of GLP-1 receptor agonists in inducing weight loss but often did not address maintenance strategies beyond initial treatment phases. The STEP 4 study is unique in directly comparing continued therapy with discontinuation, providing clearer guidance on long-term management strategies.

Our Analysis

PeptideVault views this research as a significant step forward in understanding the role of GLP-1 receptor agonists like semaglutide for weight loss maintenance. However, it is crucial to acknowledge that further studies are needed to confirm these findings over longer periods and across diverse patient populations, including those with diabetes.

Key Takeaways

  • Sustained Therapy: Continued use of semaglutide can help maintain significant weight loss achieved during initial treatment phases.
  • Health Benefits: Beyond weight management, the study indicates additional health benefits such as improved waist circumference and blood pressure control.
  • Further Research Needed: Longer-term studies are essential to fully understand the long-term efficacy and safety of GLP-1 receptor agonists.

Original Source

Citation: Rubino Domenica, Abrahamsson Niclas, Davies Melanie et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.. JAMA. DOI: 10.1001/jama.2021.3224

Access: https://pubmed.ncbi.nlm.nih.gov/33755728/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the PeptideVault research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on semaglutide, explore our research guides.

Citation

Rubino Domenica, Abrahamsson Niclas, Davies Melanie et al.. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.. JAMA. https://doi.org/10.1001/jama.2021.3224

View full text on PubMed

Related Papers

Medications for Obesity: A Review.

Gudzune Kimberly A et al. · JAMA · 2024

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Misra Saurav et al. · Journal of basic and clinical physiology and pharmacology · 2025

A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist.

Min Jee Sun et al. · Drug design, development and therapy · 2025

Retatrutide-A Game Changer in Obesity Pharmacotherapy.

Katsi Vasiliki et al. · Biomolecules · 2025

Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.

Thomsen Reimar W et al. · Diabetes, obesity & metabolism · 2025

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.